Evolution Biotechnologies announces expansion of operations in the United States

Austin, Texas, 17th January 2020

Evolution Biotechnologies the company extending the use of biological control into medically important areas, today announced the opening of Evolution Biotechnologies Inc., of Austin, Texas. The company is focussed on phage therapy, initially targeting the antibiotic resistant superbug Pseudomonas aeruginosa. This will initially target disease in companion animals as a basis for the later development of human therapeutics.

Further details can be found on the company website at www.evolutionbiotech.us.

Dr. David Harper, CEO, said “This is an important step forward for Evolution Biotechnologies, and for phage therapy as a whole, bringing the unique expertise resulting from our successful previous work to this important area, working to save and improve lives worldwide”.

About Evolution Biotechnologies

Evolution Biotechnologies Inc. (Registered USA No. 6050853) is working to bring phage therapy to market, using its unique, low-cost approach. The company’s initial target is antibiotic-resistant Pseudomonas aeruginosa infections in the canine ear. Once this has moved to commercial applications, company revenue will be used to support expansion into therapeutics intended for human use.

About phage therapy

Phage therapy is one of the most promising approaches to fighting antibiotic resistance. The basic approach has been around since 1919, but despite its long history and positive results from individual under ”Expanded Access” programs there has only been one successful modern clinical trial to demonstrate the efficacy of phage therapeutics. This was in a phase 1/2 clinical trial targeting drug-resistant Pseudomonas aeruginosa infections in both dog and human ear infections. These trials were managed by Evolution’s CEO, Dr. David Harper in a previous role. This unique experience underpins the work of Evolution Biotechnologies in moving phage therapy towards market.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.us

Website: www.evolutionbiotech.us